Session Idle Alert

You will be logged out in due to inactivity. Please click Ok to extend the session or select Log Out to end the session.


Top 25

Most Frequently Identified Drugs Submitted to laboratories from January 1, 2020, through December 31, 2020, and analyzed by March 30, 2021.

283 98.5%



Drug cases during 2020 identified an estimated 1,009,958 drug reports.

Methamphetamine was the most frequently identified drug (41%). Fentanyl was fourth most frequently identified drug and most frequently reported prescription drug. MDMB-4en-PINACA was the most frequently reported synthetic cannabinoid.

Link to annual report

8 New NFLIS-DRUG Reports

The following 8 drugs were reported for the first time between July 1, 2021 and September 30, 2021:

  • 1-Phenethyl-4-hydroxypiperidine
  • 1-Phenethyl-4-propionyloxypiperidine
  • Fluoro 4-anilinopiperidine
  • N-Pyrrolidino etonitazene
  • Butonitazene

NFLIS-Drug Snapshot (September 2021)

NFLIS began in September 1997 as a single data collection effort of drug chemistry analysis results from local, State, and Federal forensic laboratories (now called NFLIS-Drug). These laboratories analyze substances secured in law enforcement operations across the country. Since its inception, NFLIS-Drug has become an operational information system that includes data from forensic laboratories that conduct analyses of about 98 percent of the Nation's approximate 1.3 million annual drug cases. As of September 2021, NFLIS-Drug includes voluntary participation from 50 State systems and 108 local or municipal laboratories/laboratory systems, representing a total of 283 individual laboratories. The NFLIS program is expanding the scope of data collection to include public and private toxicology laboratory data on toxicological findings from antemortem and postmortem drug testing (NFLIS-Tox) and medical examiner and coroner office data regarding deaths in which drugs were identified (NFLIS-MEC). NFLIS-Tox recruitment is currently underway with over 80 laboratories signing on to participate. NFLIS-MEC recruitment will begin in January 2022.

NFLIS-Drug provides the community with midyear and annual reports highlighting trends in seized drug data submitted to and analyzed by laboratories. Special reports and briefs respond to national drug crises such as fentanyl and fentanyl-related compounds, and synthetic cannabinoids and synthetic cathinones. The NFLIS-Drug Snapshots highlight new and emerging drugs, and the public data tables show drug reports by state from 2007-2020.

If your laboratory would like to participate in NFLIS, review DEA's FAQs document to determine your entity's eligibility to participate in NFLIS and to review other information about each NFLIS component and the next steps for participation. You may also contact DEA at

Participating Laboratories, by U.S. Census Region